--2024/Q4-- / 82.374B--
--2024/Q3-- / 73.624B--
Aug 7, 20242024/Q268.060B / 68.563B--
May 2, 20242024/Q165.349B / 63.573B--
Jan 31, 20242023/Q465.863B / 61.207B
Replay
Novo Nordisk Q4 2023 earnings conference call
Jan 31 06:00
ReplayUS Stock MarketDetailed Quotes
NVO Novo-Nordisk A/S
- 136.970
- +0.090+0.07%
Close Aug 23 16:00 ET
- 136.550
- -0.420-0.31%
Post 20:01 ET
610.36BMarket Cap45.79P/E (TTM)
137.145High135.920Low2.11MVolume136.570Open136.880Pre Close288.41MTurnover0.07%Turnover Ratio49.39P/E (Static)4.46BShares147.59352wk High36.42P/B436.92BFloat Cap86.01252wk Low1.36Dividend TTM3.19BShs Float147.593Historical High0.99%Div YieldTTM0.90%Amplitude-3.073Historical Low136.543Avg Price1Lot Size
Novo-Nordisk A/S Key Stats
Novo-Nordisk A/S Q2 2024 Earnings Date
Highlights | Novo Nordisk reported lower-than-expected sales of its popular weight-loss drug Wegory, raising concerns about rising competition from Eli Lilly
Currency：DKKAug 7, 2024
| Estimate (YoY) | Actual (YoY) | Vs Estimate (% Chg) | |
| Revenue | 68.56B | 68.06B | -503.19M |
| Miss Est. | +26.27% | +25.34% | -0.73% |
| EPS | 5.01 | 4.49 | -0.52 |
| Miss Est. | +16.19% | +3.94% | -10.45% |
Analyst Rating
Aug 8, 2024
Novo-Nordisk A/S Earnings Estimates
Revenue
EPS
EBIT
Revenue is based on 10 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement
Currency: DKK
Actual
Estimate
Unlock Free Earnings Estimates
Open Account
Novo-Nordisk A/S Earnings Reports
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
